Alicia C Marin1,2, Olga P Nyssen1,2, Adrian G McNicholl3,4, Javier P Gisbert1,2. 1. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. 3. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. adrian.mcn@gmail.com. 4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. adrian.mcn@gmail.com.
Abstract
BACKGROUND: Anti-Helicobacter pylori eradication treatment fails in a significant percentage of cases. Although this percentage has been reduced to 5-15% with the use of non-bismuth quadruple therapies, limited data exist regarding rescue after failure of these treatments. AIM: The aim of this study was to systematically review the efficacy and safety of quinolone-containing therapies after the failure of non-bismuth quadruple regimens. METHODS: Studies evaluating the efficacy of second-line quinolone-containing therapies after the failure of non-bismuth sequential or concomitant regimens were selected. Efficacy (by intention to treat) was analyzed using the inverse variance method; safety data were recorded as the occurrence of any adverse event. The risk of bias of each primary study was evaluated using the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) tool. The quality of the evidence was summarized using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. RESULTS: Sixteen studies were included. The 10-day levofloxacin/amoxicillin/proton pump inhibitor (PPI) triple therapy (LT) achieved eradication rates of 80% (95% CI 71-88). Regarding the moxifloxacin/amoxicillin/PPI triple therapy (MT), its efficacy was higher when administered for 14 days instead of 7 days (80 vs 63%). Two studies investigated the levofloxacin/bismuth-containing quadruple therapies (LBQ) obtaining eradication rates over 90%. Safety was similar in all treatments. The sensitivity analyses showed that results for LT were robust, but MT had weak evidence. CONCLUSIONS: Quinolone-containing triple therapies reported eradication rates ≤80%, but LBQ therapies showed encouraging rates. However, the strength of the evidence was very low. The efficacy of LBQ should be corroborated in more studies, and the usefulness of quinolones needs to be evaluated in areas with moderate to high bacterial resistances.
BACKGROUND: Anti-Helicobacter pylori eradication treatment fails in a significant percentage of cases. Although this percentage has been reduced to 5-15% with the use of non-bismuth quadruple therapies, limited data exist regarding rescue after failure of these treatments. AIM: The aim of this study was to systematically review the efficacy and safety of quinolone-containing therapies after the failure of non-bismuth quadruple regimens. METHODS: Studies evaluating the efficacy of second-line quinolone-containing therapies after the failure of non-bismuth sequential or concomitant regimens were selected. Efficacy (by intention to treat) was analyzed using the inverse variance method; safety data were recorded as the occurrence of any adverse event. The risk of bias of each primary study was evaluated using the Risk of Bias in Non-randomized Studies-of Interventions (ROBINS-I) tool. The quality of the evidence was summarized using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. RESULTS: Sixteen studies were included. The 10-day levofloxacin/amoxicillin/proton pump inhibitor (PPI) triple therapy (LT) achieved eradication rates of 80% (95% CI 71-88). Regarding the moxifloxacin/amoxicillin/PPI triple therapy (MT), its efficacy was higher when administered for 14 days instead of 7 days (80 vs 63%). Two studies investigated the levofloxacin/bismuth-containing quadruple therapies (LBQ) obtaining eradication rates over 90%. Safety was similar in all treatments. The sensitivity analyses showed that results for LT were robust, but MT had weak evidence. CONCLUSIONS:Quinolone-containing triple therapies reported eradication rates ≤80%, but LBQ therapies showed encouraging rates. However, the strength of the evidence was very low. The efficacy of LBQ should be corroborated in more studies, and the usefulness of quinolones needs to be evaluated in areas with moderate to high bacterial resistances.
Authors: Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers Journal: Gut Date: 2012-05 Impact factor: 23.059
Authors: Gordon H Guyatt; Andrew D Oxman; Holger J Schünemann; Peter Tugwell; Andre Knottnerus Journal: J Clin Epidemiol Date: 2010-12-24 Impact factor: 6.437
Authors: Javier P Gisbert; Javier Molina-Infante; Javier Amador; Fernando Bermejo; Luis Bujanda; Xavier Calvet; Manuel Castro-Fernández; Antonio Cuadrado-Lavín; J Ignasi Elizalde; Emili Gene; Fernando Gomollón; Ángel Lanas; Carlos Martín de Argila; Fermín Mearin; Miguel Montoro; Ángeles Pérez-Aisa; Emilio Pérez-Trallero; Adrián G McNicholl Journal: Gastroenterol Hepatol Date: 2017-03-11 Impact factor: 2.102
Authors: J P Gisbert; M Romano; A G Gravina; P Solís-Muñoz; F Bermejo; J Molina-Infante; M Castro-Fernández; J Ortuño; A J Lucendo; M Herranz; I Modolell; F Del Castillo; J Gómez; J Barrio; B Velayos; B Gómez; J L Domínguez; A Miranda; M Martorano; A Algaba; M Pabón; T Angueira; L Fernández-Salazar; A Federico; A C Marín; A G McNicholl Journal: Aliment Pharmacol Ther Date: 2015-02-23 Impact factor: 8.171
Authors: Ji Hyun Lim; Dong Ho Lee; Seong Tae Lee; Nayoung Kim; Young Soo Park; Cheol Min Shin; In Sung Song Journal: World J Gastroenterol Date: 2015-12-14 Impact factor: 5.742
Authors: Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins Journal: BMJ Date: 2016-10-12
Authors: María Caldas; Ángeles Pérez-Aisa; Manuel Castro-Fernández; Luis Bujanda; Alfredo J Lucendo; Luis Rodrigo; Jose M Huguet; Jorge Pérez-Lasala; Javier Molina-Infante; Jesús Barrio; Luis Fernández-Salazar; Ángel Lanas; Mónica Perona; Manuel Domínguez-Cajal; Juan Ortuño; Blas José Gómez-Rodríguez; Pedro Almela; Josep María Botargués; Óscar Núñez; Inés Modolell; Judith Gómez; Rafael Ruiz-Zorrilla; Cristóbal De la Coba; Alain Huerta; Eduardo Iyo; Liliana Pozzati; Rosario Antón; Mercé Barenys; Teresa Angueira; Miguel Fernández-Bermejo; Ana Campillo; Javier Alcedo; Ramón Pajares-Villaroya; Marianela Mego; Fernando Bermejo; José Luis Dominguez-Jiménez; Llúcia Titó; Nuria Fernández; Manuel Pabón-Carrasco; Ángel Cosme; Pilar Mata-Romero; Noelia Alcaide; Inés Ariño; Tommaso Di Maira; Ana Garre; Ignasi Puig; Olga P Nyssen; Francis Megraud; Colm O'Morain; Javier P Gisbert Journal: Antibiotics (Basel) Date: 2020-12-25